Renaissance Technologies’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-146,415
| Closed | -$2.97M | – | 4547 |
|
|
2022
Q4 | $2.97M | Sell |
146,415
-30,500
| -17% | -$468K | ﹤0.01% | 1827 |
|
|
2022
Q3 | $1.9M | Sell |
176,915
-16,500
| -9% | -$187K | ﹤0.01% | 2044 |
|
|
2022
Q2 | $2.32M | Buy |
193,415
+15,400
| +9% | +$248K | ﹤0.01% | 2082 |
|
|
2022
Q1 | $3.81M | Sell |
178,015
-5,800
| -3% | -$154K | ﹤0.01% | 1776 |
|
|
2021
Q4 | $6.18M | Sell |
183,815
-21,800
| -11% | -$607K | 0.01% | 1385 |
|
|
2021
Q3 | $5.29M | Buy |
205,615
+14,300
| +7% | +$256K | 0.01% | 1433 |
|
|
2021
Q2 | $2.56M | Sell |
191,315
-31,500
| -14% | -$389K | ﹤0.01% | 2079 |
|
|
2021
Q1 | $2.37M | Sell |
222,815
-14,000
| -6% | -$160K | ﹤0.01% | 2116 |
|
|
2020
Q4 | $1.9M | Buy |
236,815
+20,900
| +10% | +$164K | ﹤0.01% | 2149 |
|
|
2020
Q3 | $1.62M | Buy |
215,915
+27,945
| +15% | +$248K | ﹤0.01% | 2255 |
|
|
2020
Q2 | $1.7M | Buy |
187,970
+126,742
| +207% | +$1.31M | ﹤0.01% | 2263 |
|
|
2020
Q1 | $587K | Buy |
61,228
+20,200
| +49% | +$242K | ﹤0.01% | 2680 |
|
|
2019
Q4 | $591K | Buy |
41,028
+25,819
| +170% | +$376K | ﹤0.01% | 2836 |
|
|
2019
Q3 | $229K | Buy |
+15,209
| New | +$212K | ﹤0.01% | 3109 |
|
Renaissance Technologies's OPNT Position: Q1 2023 in Review
Renaissance Technologies sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2023, closing a stake of 146,415 shares — an estimated $2.97M sold.
Renaissance Technologies first reported a position in OPNT in Q3 2019 and held it in 14 quarters. The position peaked at $6.18M in Q4 2021. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.
- Renaissance Technologies reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- Renaissance Technologies sold 146,415 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $2.97M.
- Renaissance Technologies first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 14 quarters.
- Renaissance Technologies's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $6.18M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2023.
Based on Renaissance Technologies's 13F filing for Q1 2023, filed 12 May 2023.